Anil A. Joy

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Hope S. Rugo, Richard S. Finn, Véronique Dièras et al. · Breast Cancer Research and Treatment · 2019 · 415 citations · Full text

Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions

Lee W. Jones, Carolyn J. Peddle‐McIntyre, Neil D. Eves et al. · Cancer · 2007 · 325 citations · Full text

Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer

Eva Grunfeld, Jim A. Julian, Gregory R. Pond et al. · Journal of Clinical Oncology · 2011 · 312 citations · Full text

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

Monica Mita, Anil A. Joy, Alain C. Mita et al. · Clinical Breast Cancer · 2013 · 151 citations

Advanced Breast Cancer, Breast Oncology, Oncology +8